{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-141306","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.728497+00:00","generated_at":"2026-06-25T23:33:44.777084+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Agios reports Q1 net loss $94.8M; PYRUKYND launch revenue $0.8M, cash $1.2B","bullets":["FDA approved PYRUKYND for PK deficiency in Feb 2022; U.S. launch generated $0.8M net revenue in partial quarter.","Net loss from continuing ops $94.8M vs $90.9M YoY; R&D spend $70.1M, SG&A $31.5M.","Cash & securities $1.2B (down from $2.4B YoY) due to $802.5M share repurchases in 2021; no need for equity.","Key 2022 milestones: EMA decision on PYRUKYND by year-end, start pediatric PK studies mid-2022.","Phase 2a study of AG-946 in MDS to initiate by year-end; AG-946 Phase 1 sickle cell cohort started."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-141306","json":"https://secwatch.observer/filing/0001193125-22-141306.json","markdown":"https://secwatch.observer/filing/0001193125-22-141306.md","text":"https://secwatch.observer/filing/0001193125-22-141306.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522141306/0001193125-22-141306-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522141306/d266362d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:33:44.777084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}